- Home
- RIGL vs GEVO Comparison
RIGL vs GEVO Comparison
Compare RIGL & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- GEVO
- Stock Information
- Founded
- RIGL 1996
- GEVO 2005
- Country
- RIGL United States
- GEVO United States
- Employees
- RIGL N/A
- GEVO N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- GEVO Major Chemicals
- Sector
- RIGL Health Care
- GEVO Industrials
- Exchange
- RIGL Nasdaq
- GEVO Nasdaq
- Market Cap
- RIGL 335.5M
- GEVO 418.4M
- IPO Year
- RIGL 2000
- GEVO 2011
- Fundamental
- Price
- RIGL $38.85
- GEVO $1.73
- Analyst Decision
- RIGL Buy
- GEVO Buy
- Analyst Count
- RIGL 5
- GEVO 2
- Target Price
- RIGL $38.20
- GEVO $7.58
- AVG Volume (30 Days)
- RIGL 995.6K
- GEVO 9.4M
- Earning Date
- RIGL 08-05-2025
- GEVO 08-11-2025
- Dividend Yield
- RIGL N/A
- GEVO N/A
- EPS Growth
- RIGL N/A
- GEVO N/A
- EPS
- RIGL 5.43
- GEVO N/A
- Revenue
- RIGL $267,921,000.00
- GEVO $80,187,000.00
- Revenue This Year
- RIGL $59.93
- GEVO $909.99
- Revenue Next Year
- RIGL N/A
- GEVO $22.37
- P/E Ratio
- RIGL $7.15
- GEVO N/A
- Revenue Growth
- RIGL 105.62
- GEVO 341.75
- 52 Week Low
- RIGL $12.66
- GEVO $0.67
- 52 Week High
- RIGL $43.72
- GEVO $3.39
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- GEVO 57.77
- Support Level
- RIGL $39.00
- GEVO $1.54
- Resistance Level
- RIGL $42.08
- GEVO $1.86
- Average True Range (ATR)
- RIGL 2.32
- GEVO 0.14
- MACD
- RIGL -0.37
- GEVO 0.01
- Stochastic Oscillator
- RIGL 53.26
- GEVO 31.15
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.